These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 16731954)

  • 1. Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses.
    Deeks SG; Schweighardt B; Wrin T; Galovich J; Hoh R; Sinclair E; Hunt P; McCune JM; Martin JN; Petropoulos CJ; Hecht FM
    J Virol; 2006 Jun; 80(12):6155-64. PubMed ID: 16731954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections.
    Rodriguez SK; Sarr AD; MacNeil A; Thakore-Meloni S; Gueye-Ndiaye A; Traoré I; Dia MC; Mboup S; Kanki PJ
    J Virol; 2007 May; 81(10):5331-8. PubMed ID: 17301136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing antibody patterns and viral escape in HIV-1 non-B subtype chronically infected treatment-naive individuals.
    Kelly HR; Urbanski M; Burda S; Zhong P; Konings F; Nanfack J; Tongo M; Kinge T; Achkar J; Nyambi P
    Hum Antibodies; 2005; 14(3-4):89-99. PubMed ID: 16720979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes.
    Ruppach H; Nara P; Raudonat I; Elanjikal Z; Rübsamen-Waigmann H; Dietrich U
    J Virol; 2000 Jun; 74(12):5403-11. PubMed ID: 10823844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual.
    Montefiori DC; Altfeld M; Lee PK; Bilska M; Zhou J; Johnston MN; Gao F; Walker BD; Rosenberg ES
    J Immunol; 2003 Apr; 170(7):3906-14. PubMed ID: 12646660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity.
    Sagar M; Wu X; Lee S; Overbaugh J
    J Virol; 2006 Oct; 80(19):9586-98. PubMed ID: 16973562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.
    Moog C; Fleury HJ; Pellegrin I; Kirn A; Aubertin AM
    J Virol; 1997 May; 71(5):3734-41. PubMed ID: 9094648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism.
    Marcelino JM; Borrego P; Nilsson C; Família C; Barroso H; Maltez F; Doroana M; Antunes F; Quintas A; Taveira N
    AIDS; 2012 Nov; 26(18):2275-84. PubMed ID: 23151495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous IgG antibodies block outgrowth of a substantial but variable fraction of viruses in the latent reservoir for HIV-1.
    Bertagnolli LN; Varriale J; Sweet S; Brockhurst J; Simonetti FR; White J; Beg S; Lynn K; Mounzer K; Frank I; Tebas P; Bar KJ; Montaner LJ; Siliciano RF; Siliciano JD
    Proc Natl Acad Sci U S A; 2020 Dec; 117(50):32066-32077. PubMed ID: 33239444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies.
    Kraft Z; Derby NR; McCaffrey RA; Niec R; Blay WM; Haigwood NL; Moysi E; Saunders CJ; Wrin T; Petropoulos CJ; McElrath MJ; Stamatatos L
    J Virol; 2007 Jun; 81(12):6402-11. PubMed ID: 17392364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes.
    de Silva TI; Aasa-Chapman M; Cotten M; Hué S; Robinson J; Bibollet-Ruche F; Sarge-Njie R; Berry N; Jaye A; Aaby P; Whittle H; Rowland-Jones S; Weiss R
    J Virol; 2012 Jan; 86(2):930-46. PubMed ID: 22072758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid evolution of the neutralizing antibody response to HIV type 1 infection.
    Richman DD; Wrin T; Little SJ; Petropoulos CJ
    Proc Natl Acad Sci U S A; 2003 Apr; 100(7):4144-9. PubMed ID: 12644702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection.
    Pilgrim AK; Pantaleo G; Cohen OJ; Fink LM; Zhou JY; Zhou JT; Bolognesi DP; Fauci AS; Montefiori DC
    J Infect Dis; 1997 Oct; 176(4):924-32. PubMed ID: 9333150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.
    Sather DN; Armann J; Ching LK; Mavrantoni A; Sellhorn G; Caldwell Z; Yu X; Wood B; Self S; Kalams S; Stamatatos L
    J Virol; 2009 Jan; 83(2):757-69. PubMed ID: 18987148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection.
    Montefiori DC; Hill TS; Vo HT; Walker BD; Rosenberg ES
    J Virol; 2001 Nov; 75(21):10200-7. PubMed ID: 11581388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrasubtype B HIV-1 Superinfection Correlates with Delayed Neutralizing Antibody Response.
    Wagner GA; Landais E; Caballero G; Phung P; Kosakovsky Pond SL; Poignard P; Richman DD; Little SJ; Smith DM
    J Virol; 2017 Sep; 91(17):. PubMed ID: 28615205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of autologous neutralizing antibodies in the cerebrospinal fluid of HIV-1 infected individuals.
    von Gegerfelt A; Chiodi F; Keys B; Norkrans G; Hagberg L; Fenyö EM; Broliden K
    AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1133-8. PubMed ID: 1503825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers.
    Mahalanabis M; Jayaraman P; Miura T; Pereyra F; Chester EM; Richardson B; Walker B; Haigwood NL
    J Virol; 2009 Jan; 83(2):662-72. PubMed ID: 18987151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env Genetic subtype B and E viruses in Thailand.
    Auewarakul P; Louisirirotchanakul S; Sutthent R; Taechowisan T; Kanoksinsombat C; Wasi C
    Viral Immunol; 1996; 9(3):175-85. PubMed ID: 8890476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape.
    Arendrup M; Sönnerborg A; Svennerholm B; Akerblom L; Nielsen C; Clausen H; Olofsson S; Nielsen JO; Hansen JE
    J Gen Virol; 1993 May; 74 ( Pt 5)():855-63. PubMed ID: 7684062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.